Clinical Trial

Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma

Study acronym: RHUMM
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 13, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of the study is to evaluate at Day 1 Cycle 2, the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-hour urine, in patients with Multiple Myeloma.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-01-12; most recent amendment 2026-04-08.
Status change: Recruiting → Active, Not Recruiting 2026-04-08
Status change: Not Yet Recruiting → Recruiting 2022-07-20
Trial Details
NCT Number NCT05208086
Lead Sponsor Intergroupe Francophone du Myelome
Conditions Multiple Myeloma
Enrollment 180 participants
Start Date 2022-05-18
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-13